Surgery, Franciscus Gasthuis en Vlietland, Rotterdam, The Netherlands
Pharmacology, Franciscus Gasthuis en Vlietland, Rotterdam, The Netherlands.
BMJ Open. 2020 Feb 5;10(2):e034572. doi: 10.1136/bmjopen-2019-034572.
Fast-track protocols often include short-term thromboprophylaxis and short length of hospital stay. These treatment strategies may negatively affect the occurrence and diagnosis of postoperative haemorrhage. Over the years, the rates of venous thromboembolic events (VTEs) have decreased, while there seems to be an increase in the occurrence of postoperative haemorrhage. Tranexamic acid (TXA) can potentially lower the incidence of postoperative haemorrhage. This trial aims to investigate whether preoperative administration of TXA reduces the preoperative and postoperative haemorrhage rates in laparoscopic sleeve gastrectomy (LSG).
This is a single centre double-blind randomised placebo-controlled trial. Patients undergoing an LSG are included after obtaining informed consent. Patients are randomised between two groups: (1) administration of placebo infusion and (2) administration of 1500 mg TXA. In both groups, the infusions will be administered during the induction phase of the procedure. Primary outcome measures are preoperative use of haemostatic clips, postoperative haemoglobin decrease and postoperative haemorrhage. Secondary outcome measure is the rates of VTE.
The protocol version 3 was approved by the medical ethical committee Medical Research Ethics Committees United (MEC-U), Nieuwegein, on 29 July 2019. The trial results will be submitted for publication in a peer-reviewed journal and at conference presentations.
The Netherlands Trial Registry (NL8029); Pre-results.
快速通道方案通常包括短期的血栓预防和短时间的住院治疗。这些治疗策略可能会对术后出血的发生和诊断产生负面影响。多年来,静脉血栓栓塞事件(VTE)的发生率有所下降,而术后出血的发生率似乎有所上升。氨甲环酸(TXA)可能会降低术后出血的发生率。本试验旨在研究术前给予 TXA 是否会降低腹腔镜袖状胃切除术(LSG)中的术前和术后出血率。
这是一项单中心、双盲、随机、安慰剂对照试验。在获得知情同意后,将接受 LSG 的患者纳入研究。患者随机分为两组:(1)给予安慰剂输注;(2)给予 1500mg TXA。在两组中,输注将在手术诱导阶段进行。主要观察指标为术前使用止血夹、术后血红蛋白下降和术后出血。次要观察指标为 VTE 的发生率。
该方案的第 3 版于 2019 年 7 月 29 日由医学伦理委员会医学研究伦理委员会联合(MEC-U)批准。试验结果将提交给同行评议的期刊发表,并在会议上展示。
荷兰试验注册处(NL8029);预结果。